Volume 21 Issue 11 November 2010
REVIEWS
Docetaxel-based combination therapy for castration-resistant prostate cancer
M. D. Galsky and N. J. Vogelzang
Ann Oncol (2010) 21(11): 2135-2144 first published online March 29, 2010 doi:10.1093/annonc/mdq050 Abstract
Optimising the dose of capecitabine in metastatic breast cancer: confused, clarified or confirmed?
C. Zielinski, J. Gralow, and M. Martin
Ann Oncol (2010) 21(11): 2145-2152 first published online March 23, 2010 doi:10.1093/annonc/mdq069 Abstract
Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer
R. B. Costa, G. Kurra, L. Greenberg, and C. E. Geyer
Ann Oncol (2010) 21(11): 2153-2160 first published online March 29, 2010 doi:10.1093/annonc/mdq096 Abstract
Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study
Eidtmann, R. de Boer, N. Bundred, A. Llombart-Cussac, N. Davidson, P. Neven, G. von Minckwitz, J. Miller, N. Schenk, and R. Coleman Ann Oncol (2010)21(11):2188-2194first published online May 5, 2010 doi:10.1093/annonc/mdq217 Abstract
J. Sehouli, K. Pietzner, P. Harter, K. Münstedt, S. Mahner, A. Hasenburg, O. Camara, P. Wimberger, D. Boehmer, K. J. Buehling, R. Richter, K. El Khalfaoui, and G. Oskay-Ozcelik
Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study Ann Oncol (2010) 21(11): 2201-2205 first published online May 3, 2010 doi:10.1093/annonc/mdq229 Abstract
Improved survival of colon cancer due to improved treatment and detection: a nationwide population-based study in The Netherlands 1989–2006
L. N. van Steenbergen, M. A. G. Elferink, P. Krijnen, V. E. P. P. Lemmens, S. Siesling, H. J. T. Rutten, D. J. Richel, H. E. Karim-Kos, J. W. W. Coebergh, and on behalf of the Working Group Output of The Netherlands Cancer Registry
Ann Oncol (2010) 21(11): 2206-2212 first published online May 3, 2010 doi:10.1093/annonc/mdq227
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
S. Rao, N. Starling, D. Cunningham, K. Sumpter, D. Gilligan, T. Ruhstaller, M. Valladares-Ayerbes, H. Wilke, C. Archer, R. Kurek, C. Beadman, and J. Oates
Ann Oncol (2010) 21(11): 2213-2219 first published online May 23, 2010 doi:10.1093/annonc/mdq247 Abstract
Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial
G. P. Stathopoulos, D. Antoniou, J. Dimitroulis, P. Michalopoulou, A. Bastas, K. Marosis, J. Stathopoulos, A. Provata, P. Yiamboudakis, D. Veldekis, N. Lolis, N. Georgatou, M. Toubis, Ch. Pappas, and G. Tsoukalas
Ann Oncol (2010) 21(11): 2227-2232 first published online May 3, 2010 doi:10.1093/annonc/mdq234 Abstract
Response assessment by combined PET–CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy
V. A. Passero, B. F. Branstetter, Y. Shuai, D. E. Heron, M. K. Gibson, S. Y. Lai, S. W. Kim, J. R. Grandis, R. L. Ferris, J. T. Johnson, and A. Argiris
Ann Oncol (2010) 21(11): 2278-2283 first published online April 29, 2010 doi:10.1093/annonc/mdq226 Abstract
Concomitant chemoradiation versus radical radiotherapy in advanced squamous cell carcinoma of oropharynx and nasopharynx using weekly cisplatin: a phase II randomized trial
A. Sharma, B. K. Mohanti, A. Thakar, S. Bahadur, and S. Bhasker Ann Oncol (2010)21(11):2272-2277first published online April 28, 2010 doi:10.1093/annonc/mdq219 Abstract
